Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.30 USD

73.30
7,219,345

+1.66 (2.32%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $73.43 +0.13 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Wall Street Waits for Major Economic Data This Week

Wall Street Waits for Major Economic Data This Week.

Should Value Investors Pick Gilead Sciences (GILD) Stock?

Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Nalak Das headshot

5 Corporate Giants Likely to Gain From Q4 Earnings Next Week

Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead

Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $68.57, moving +0.09% from the previous trading session.

Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $71.77, marking a -0.15% move from the previous day.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $72.37 in the latest trading session, marking a +0.39% move from the prior day.

Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study

Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.

Why Gilead (GILD) is Poised to Beat Earnings Estimates Again

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Spero (SPRO) Application for UTI Drug Gets Priority Review

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.58, moving -0.04% from the previous trading session.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab

J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.

Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices

Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $73.64, marking a +0.92% move from the previous day.